Genzyme To Acquire Ilex Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme will pay $1 bil. for its first oncology therapeutic agent through the acquisition of Ilex Oncology
You may also be interested in...
Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Genzyme Asks For Campath Label Expansion To First-Line Lymphocytic Leukemia
Data supporting the B-cell lymphocytic leukemia sBLA also completes Campath’s 2001 Phase IV obligation.